• Outstanding Seal
  • Antimicrobial properties
  • Promotes per-apical healing
  • Easy obturations and follow-up


BioRoot™ RCS. Succeed.


For more information on this exciting new product go to 
www.septodont.com

 

Article: Volume 45 Number 2 Page 102 - February 2018

Prev    Article P102    Next  Read article

  Dent Update 2018; 45: 102-117

Oral Surgery /Restorative Dentistry:  Medication-Related OsteoNecrosis of the Jaw (MRONJ): Realities, Risks and Responsibilities

CPD:  CPD  0:24   (closed)      Self assess

Feedback:  0 comments, 1 rating    

      

Abstract: Considerable concern and confusion exists about Medication-Related OsteoNecrosis of the Jaw (MRONJ) which can be a painful, prolonged and debilitating condition caused by the death of jaw bone. The most common class of drugs causing this rare problem is the bisphosphonate group of drugs, which resulted in the term Bisphosphonate-Related OsteoNecrosis of the Jaw previously being given the acronym BRONJ.

Clinical relevance: This article will help to update healthcare practitioners on assessing the realistic risks of patients developing MRONJ. It offers some ideas on reducing those risks in a practical way.

Author notes: Lakshmi Rasaratnam, BDS Lond(Hons), MJDF, Specialty Registrar in Restorative Dentistry, Martin Kelleher, BDS(Hons), MSc, FDS RCPS, FDS RCS, FDS RCS, Consultant in Restorative Dentistry and Sarah Taylor, BDS, MFDS, DipDSed, Specialty Doctor in Oral Surgery, Department of Restorative Dentistry, King’s College Hospital, London SE5 9RW, UK.

Objective: Medication-Related OsteoNecrosis of the Jaw (MRONJ): Realities, Risks and Responsibilities L Rasaratnam, M Kelleher and S Taylor CPD Aims, Objectives and Learning Outcomes: To explain Medication-Related OsteoNecrosis of the Jaw (MRONJ). Enhanced CPD DO C

BDIA CSIDI